Guo, Sijin http://orcid.org/0000-0003-0075-2299
Vieweger, Mario http://orcid.org/0000-0002-0510-9633
Zhang, Kaiming http://orcid.org/0000-0003-0414-4776
Yin, Hongran http://orcid.org/0000-0001-5417-2754
Wang, Hongzhi http://orcid.org/0000-0002-4383-9784
Li, Xin http://orcid.org/0000-0001-5085-5734
Li, Shanshan http://orcid.org/0000-0002-7041-5960
Hu, Shuiying http://orcid.org/0000-0002-9806-7734
Sparreboom, Alex http://orcid.org/0000-0003-2660-6644
Evers, B. Mark http://orcid.org/0000-0002-9425-2342
Dong, Yizhou http://orcid.org/0000-0001-5786-0659
Chiu, Wah http://orcid.org/0000-0002-8910-3078
Guo, Peixuan http://orcid.org/0000-0001-5706-2833
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01CA195573, U01CA207946, R01EB019036, R01CA195573)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (S10OD021600, P41GM103832)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Article History
Received: 27 March 2019
Accepted: 24 January 2020
First Online: 20 February 2020
Competing interests
: P.G. is the consultant of Oxford Nanopore Technologies, the co-founder of Shenzhen P&Z Bio-medical Co. Ltd, and the co-founder of the ExonanoRNA, LLC and its subsidiary ExonanoRNA (Foshan) Biomedicine Co., Ltd.